Evaluation of Major Pathologic Response and Pathologic Complete Response as Surrogate End Points for Survival in Randomized Controlled Trials of Neoadjuvant Immune Checkpoint Blockade in Resectable in NSCLC
Top Cited Papers
Open Access
- 8 March 2024
- journal article
- research article
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 19 (7) , 1108-1116
Abstract
No abstract availableKeywords
Funding Information
- University of Chicago
This publication has 33 references indexed in Scilit:
- Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non–Small Cell Lung CancerJAMA, 2024
- Neoadjuvant Camrelizumab Plus Platinum-Based Chemotherapy vs Chemotherapy Alone for Chinese Patients With Resectable Stage IIIA or IIIB (T3N2) Non–Small Cell Lung CancerJAMA Oncology, 2023
- Surrogacy of Pathologic Complete Response in Trials of Neoadjuvant Therapy for Early Breast CancerJAMA Oncology, 2022
- How measurement error affects inference in linear regressionEmpirical Economics, 2020
- Neoadjuvant Immunotherapy for NSCLC: Current Concepts and Future ApproachesJournal of Thoracic Oncology, 2020
- IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant TherapyJournal of Thoracic Oncology, 2020
- Agreement on Major Pathological Response in NSCLC Patients Receiving Neoadjuvant ChemotherapyClinical Lung Cancer, 2020
- Estimation of Study Time Reduction Using Surrogate End Points Rather Than Overall Survival in Oncology Clinical TrialsJAMA Internal Medicine, 2019
- Quantifying heterogeneity in a meta‐analysisStatistics in Medicine, 2002
- Practical methodology of meta‐analyses (overviews) using updated individual patient dataStatistics in Medicine, 1995